Argonaut Divests LSDx Unit to 1315 Capital, Reinvests in Fill-Finish Capacity
- Argonaut Manufacturing Services completed the sale of its Life Sciences and Diagnostics division to private equity firm 1315 Capital; the unit will operate independently as Aluris Sciences.
- Argonaut will reinvest sale proceeds into expanding aseptic fill-finish capacity and services for high-value injectable biologics at its Carlsbad, California facilities.
- No drug product programs, regulatory filings, or assets transferred; existing customer timelines, quality commitments, and contractual obligations remain unchanged.
Operational Impact
Argonaut's reinvestment of divestiture proceeds into aseptic fill-finish capacity at Carlsbad may increase available slots for biologics clients seeking dedicated or dedicated-equivalent manufacturing, though no timeline or capacity metrics were disclosed.
Source: PharmaSource RSS
Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days
- Interlabor Belp AG demonstrated a structured five-step troubleshooting workflow that runs parallel hypotheses simultaneously, eliminating sequential dead ends and compressing investigation timelines.
- Two case studies—benzene contamination in finished product and unknown residue in production pipe—showed root causes identified in 1–4 days using dedicated analytical instruments and on-site sampling.
- The model relies on flat hierarchies, fast internal approvals, and specialized equipment (IR microscope, GC-MS, SEM-EDX) reserved solely for troubleshooting rather than shared manufacturing schedules.
Operational Impact
CDMO customers relying on Interlabor for rapid contamination and residue investigation can expect root-cause identification within 1–4 days, enabling faster production restart and reduced compliance risk exposure.
Source: PharmaSource RSS